Anti-PD-1 Autoantibody Predicts Survival of Patients With Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab

Anti-PD-1 Autoantibody Predicts Survival of Patients With Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab

Background and Aims: Methods for predicting therapeutic response to immune checkpoint inhibitors in cancer therapy are in high demand. In patients with advanced hepatocellular carcinoma (HCC), atezolizumab (anti-programmed cell death-ligand 1 [PD-L1]) and bevacizumab (anti-vascular endothelial growt...

詳細記述

書誌詳細
主要な著者: Yuki Sasaki, Kazuyuki Matsumoto, Akinobu Takaki, Takuya Adachi, Masahiro Takahara, Keita Ozato, Yasuto Takeuchi, Masahiko Sue, Nozomi Miyake, Nozomu Wada, Hideki Onishi, Hidenori Shiraha, Takashi Oda, Koichiro Tsutsumi, Kazuhiro Nouso, Kazuya Kariyama, Hiroaki Hagihara, Akio Moriya, Motoyuki Otsuka
フォーマット: 論文
言語:English
出版事項: Elsevier 2024-01-01
シリーズ:Gastro Hep Advances
主題:
Immune Response
Programmed Cell Death-1
Biomarker
Immune Checkpoint Inhibitors
Overall Survival
オンライン･アクセス:http://www.sciencedirect.com/science/article/pii/S2772572324001134

インターネット

http://www.sciencedirect.com/science/article/pii/S2772572324001134

類似資料